XB-002 by Exelixis for Breast Cancer: Likelihood of Approval

XB-002 is under clinical development by Exelixis and currently in Phase II for Breast Cancer.

Dec 22, 2023 - 18:00

XB-002 is under clinical development by Exelixis and currently in Phase II for Breast Cancer.

Read the original article

Tags:

Previous Article

Iruplinalkib by Qilu Pharmaceutical for Solid Tumor: Likelihood of Approval

Imvotamab by IGM Biosciences for Rheumatoid Arthritis: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Opinion: Biden’s budget boosts funds for future pandemics, but cuts them for current ones

Opinion: Biden’s budget boosts funds for future pandemi...

Mar 28, 2023

NPX-267 by NextPoint Therapeutics for Renal Cell Carcinoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Renal Cell Carcin...

Jun 14, 2024

STAT+: FDA’s warning to J&J’s Abiomed signals a crackdown on digital health tools

STAT+: FDA’s warning to J&J’s Abiomed signals a crackdo...

Oct 16, 2023